BALLERUP, Denmark I June 03, 2025 I LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions ...

AMT-130 has been granted the FDA’s Regenerative Medicine Advance Therapy (RMAT) designation and Breakthrough Therapy designation, the first therapy for Huntington’s disease to receive an RMAT ...

NEW YORK, NY, USA I June 02, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...

– ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – ...

TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo ...

SAN DIEGO, CA, USA I June 02, 2025 I Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the ...

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance ...

NANTES, France I June 2, 2025 I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” ...

Abstract Title: Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

HOUSTON, TX, USA I June 2, 2025 I Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat ...

IMDELLTRA® (tarlatamab-dlle) U.S. Indication IMDELLTRA ® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease ...